Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …
delays the emergence of resistance and reduces toxic effects in patients who have …
Improved overall survival in melanoma with combined dabrafenib and trametinib
C Robert, B Karaszewska, J Schachter… - … England Journal of …, 2015 - Mass Medical Soc
Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as
monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E …
monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E …
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
C Robert, JJ Grob, D Stroyakovskiy… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients who have unresectable or metastatic melanoma with a BRAF V600E or
V600K mutation have prolonged progression-free survival and overall survival when …
V600K mutation have prolonged progression-free survival and overall survival when …
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
GV Long, A Hauschild, M Santinami… - … England Journal of …, 2017 - Mass Medical Soc
Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor
trametinib improved survival in patients with advanced melanoma with BRAF V600 …
trametinib improved survival in patients with advanced melanoma with BRAF V600 …
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF …
DB Johnson, KT Flaherty, JS Weber… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Preclinical and early clinical studies have demonstrated that initial therapy with
combined BRAF and MEK inhibition is more effective in BRAF V600-mutant melanoma than …
combined BRAF and MEK inhibition is more effective in BRAF V600-mutant melanoma than …
[HTML][HTML] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm …
M Schreuer, Y Jansen, S Planken, I Chevolet… - The Lancet …, 2017 - thelancet.com
Summary Background Patients with BRAF V600-mutant melanoma benefit from treatment
with the combination of BRAF and MEK inhibitors, but resistance and disease progression …
with the combination of BRAF and MEK inhibitors, but resistance and disease progression …
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
AM Menzies, GV Long - Clinical Cancer Research, 2014 - AACR
Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant
metastatic melanoma by the US Food and Drug Administration (FDA) in 2013, and most …
metastatic melanoma by the US Food and Drug Administration (FDA) in 2013, and most …
BRAF and MEK inhibition in melanoma
LA Dossett, RR Kudchadkar… - Expert opinion on drug …, 2015 - Taylor & Francis
Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition
has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma …
has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma …